Development of novel therapy for allergic skin diseases through Siglecs

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K08274
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53050:Dermatology-related
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: KATOH NORITO 京都府立医科大学, 医学(系)研究科(研究院), 教授 (30244578)
• Co-Investigator(Kenkyū-buntansha): 峠岡 理沙 京都府立医科大学, 医学(系)研究科(研究院), 講師 (80464585)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: Siglecs / 皮膚炎 / アレルギー

Outline of Final Research Achievements

The aim of the study is to study the expression of Siglecs in allergic skin diseases and to contribute to develop novel treatments by modifying Siglecs signal. We found that dermal neutrophils expressed Siglec-E in model mice of atopic dermatitis and contact dermatitis. Siglec-E mRNA was expressed significantly higher in the skin tissue of contact dermatitis model mice when compared to that of normal mice. We also found that Siglec-9 was expressed in skin tissue of patients with atopic dermatitis. We are now studying the effect of recombinant Siglec-9 in model mice of atopic dermatitis and contact dermatitis.

Free Research Field

皮膚科学

Academic Significance and Societal Importance of the Research Achievements

本研究では、自己の細胞成分によって免疫反応が生じることを防ぐための生体防御機構の一つであるSiglecs (sialic-acid-binding immunoglobulin-like lectins)の皮膚アレルギー疾患における発現を検討した。Siglecsを介するシグナルの修飾による新たな皮膚アレルギー疾患の治療法の開発につながれば、これらの疾患の治療の発展に貢献すると考えられる。